ICER’s Evaluation of Alzheimer’s Treatment Undervalues Key Groups

May 28, 2021

The Institute for Clinical and Economic Review claims that the first disease-modifying treatment for Alzheimer’s disease isn’t worth its cost. But the economists omit several key considerations about the devastating neurodegenerative disease.

View Graphic

Categorized in: Analysis

◀ Next Post

Previous Post ►